Both the over-activity and weight loss previously noted was again present, but to a lesser degree. An interesting side effect was that one of the patients developed a dark, slate-grey-purple pigmentation on the exposed surfaces of his body, identical to that described by other workers (3, 8) in patients receiving large quantities of chlorpromazine (up to 1.5 gm. per day for prolonged periods). The rapid development of this pigmentation and the small quantity of chlorpromazine involved suggests that
Results
No gross improvement was evident with either method of evaluation. Analysis of variance of the Fergus-Falls rating scale showed no significant changeover time for the group. With the standard clinical impression, one patient showed a moderate improvement, five showed a mild improvement, 17 showed no change and five patients became worse. When T. was reduced and chlorpromazine added to the regime, moderate improvement was maintained in one patient, mild improvement was lost in two cases, three continued to show mild improvement, 15 showed no change and nine showed worsening of behaviour.°T In a previous study the presence of Dosage abnormalities related to diminished thy-
The initial dose of T. was 50 meg. per roid function was demonstrated in a d d .
ay an this was increased progressively group of chronic schizophrenic subjects 100 d I I f 200 f (6) . A detailed discussion of the litera-over 'ays to a eve 0 meg. or the next 50 days. The dose was theñ~~e o~el~;~o~~~:~:a~i~~~nf~/~~et~r:~~reduced to 100 meg. per day and comf bined with chlorpromazinett for a furment 0 schizophrenia, was also given and will not be include.d here.
ther 100 days. Initially, 200 mg. of In a further study (7) tri-iodothyro-chlorpromazine per day was given. At nine (T.) was administered in slowly the end of 30 days it was increased to increasing doses to the same group of 400 mg. per day for the final 70 days. patients until a level of 100 meg. per day was reached, and this latter regime was continued for 45 days. Behaviour alteration was minimal and improvement was not noted. These studies were not therapeutic in intent and as others (1, 2) have suggested that thyroid derivatives may be of benefit in the treatment of schizophrenia, a further study with an increased amount of T.t was carried out.
Method
The same 28 chronic schizophrenic patients used in the two previous studies were again selected.
After a six-month drug-free. period, a four-month series of weekly baseline behavioural ratings were taken. These consisted of, a) the Fergus-FaIls (4) rating scale completed by a research ward nurse and, b) a clinical impression gained from discussion of the patient with the ward staff and by a brief interview with the patient by a ward physician. These latter results were assessed in the standard fashion -'worse, no change, mild, moderate or marked improvement.' the addition of the T. might have been the causative factor. This could be the result of a catalytic effect on 7-0Hchlorpromazine formation (5) or, if the purple pigment is a pseudomelanin "formed possibly by polymerization of quinoid derivatives of the phenothiazine nucleus" (5) then it is possible that the reduction in the amount of tri-iodothyronine might have released melaninstimulating hormone with increased melanin thus available for pseudomelanin formation.
Discussion
In this, as in our previous studies, To was used as the agent of choice because it acts faster and has greater stability than standard USP thyroid. Beneficial results have been claimed for T. in the treatment of psychiatric disorders (2) . The failure of response to treatment in the present study is all the more striking in that this group of patients were known to have abnormalities in thyroid function. This contrasts sharply with the results reported on by Danziger (I) who treated large samples of schizophrenics of all types and ranges of illness. He combined thyroid and thyroxine with vitamins and obtained considerable improvement. In neither of these studies were there any detailed thyroidal investigations of the patients. In the present study, as well as in previous and unpublished studiest, 60 chronic schizophrenic patients have received T. and there has only been one social recovery. It seems unlikely that T. is less effective than Danziger's preparations, but his results may be related to the fact that he treated all types of schizophrenia, including acute schizophrenics who have a high remission rate. In the present study, though the doses were not individualized, they were certainly in the high range and at a level tAn additional group of 30 chronic schizophrenic subjects have received a four-month treatment of T. at 100 meg. per day since the above study was completed. with similar results. which had been previously shown to significantly alter the abnormal thyroidal indices present in these patients. It should however be mentioned that Danziger obtained a 33% recovery in a group of patients similar to those studied here.
Despite the poor results obtained here, the fact remains that these patients have an underlying thyroid abnormality which, if corrected at an early enough period, might result in an increased remission rate. A controlled clinical trial would seem indicated.
Summary
The administration of tri-iodothyronine (T.), 200 mcgs. per day, produced minimal behavioural alteration in a group of 30 chronic schizophrenic patients with known thyroid abnormalities. The combination of 100 mcgs. of T. and 400 mgs. of chlorpromazine for three months had no beneficial effect on these patients. The above results are discussed in relation to other studies. The presence of purple pigmentation in one of the patients on combined T. and chlorpromazine is also commented upon. produit une alteration minime chez un groupe de 30 schizophrenes chroniques atreints d'anomalies thyroidiennes reconnues. La dose combinee de 100 mcg de T. et de 400 mcg de chlorpromazine pendant trois mois n'a eu aucun effet salutaire chez ces malades. L'article met ces resultats en rapport avec d'autres etudes. La presence d'une pigmentation violetre chez l'un des malades recevant ala fois de la T. et de la chlorpromazine fait egalement l'objet d'observations. 
